William Blair Reaffirms “Buy” Rating for Spark Therapeutics (NASDAQ:ONCE)

Share on StockTwits

William Blair restated their buy rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a research report released on Friday, September 21st.

Other equities analysts have also recently issued reports about the stock. ValuEngine raised shares of Spark Therapeutics from a buy rating to a strong-buy rating in a research report on Saturday, June 2nd. BMO Capital Markets lifted their price objective on shares of Spark Therapeutics from $78.00 to $98.00 and gave the stock an outperform rating in a research report on Monday, June 25th. B. Riley started coverage on shares of Spark Therapeutics in a research report on Thursday, June 28th. They set a neutral rating and a $74.00 price objective for the company. Credit Suisse Group lifted their price objective on shares of Spark Therapeutics from $75.00 to $98.00 and gave the stock an outperform rating in a research report on Monday, July 9th. Finally, Cantor Fitzgerald set a $103.00 price objective on shares of Spark Therapeutics and gave the stock a buy rating in a research report on Monday, July 16th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. Spark Therapeutics currently has an average rating of Hold and an average target price of $70.10.

NASDAQ ONCE opened at $47.94 on Friday. Spark Therapeutics has a 12-month low of $41.06 and a 12-month high of $96.59. The company has a market capitalization of $2.05 billion, a PE ratio of -6.28 and a beta of 2.24.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.34). The firm had revenue of $25.19 million for the quarter, compared to analyst estimates of $29.44 million. Spark Therapeutics had a negative return on equity of 17.33% and a negative net margin of 185.46%. Sell-side analysts predict that Spark Therapeutics will post -1.36 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can raised its stake in Spark Therapeutics by 1,045.4% during the third quarter. Bank of Montreal Can now owns 3,253 shares of the biotechnology company’s stock worth $177,000 after acquiring an additional 2,969 shares in the last quarter. Northern Trust Corp raised its stake in Spark Therapeutics by 12.3% during the second quarter. Northern Trust Corp now owns 380,819 shares of the biotechnology company’s stock worth $31,516,000 after acquiring an additional 41,723 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Spark Therapeutics by 4.9% during the second quarter. Bank of New York Mellon Corp now owns 141,367 shares of the biotechnology company’s stock worth $11,700,000 after acquiring an additional 6,613 shares in the last quarter. California Public Employees Retirement System raised its stake in Spark Therapeutics by 3.3% during the second quarter. California Public Employees Retirement System now owns 40,800 shares of the biotechnology company’s stock worth $3,377,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Putnam Investments LLC acquired a new position in Spark Therapeutics during the second quarter worth about $1,064,000.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

See Also: Stock Symbols and CUSIP Explained

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.